0001493152-23-028838.txt : 20230815 0001493152-23-028838.hdr.sgml : 20230815 20230815083012 ACCESSION NUMBER: 0001493152-23-028838 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230815 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230815 DATE AS OF CHANGE: 20230815 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Microbot Medical Inc. CENTRAL INDEX KEY: 0000883975 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943078125 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19871 FILM NUMBER: 231173288 BUSINESS ADDRESS: STREET 1: 25 RECREATION PARK DR SUITE 108 CITY: HINGHAM STATE: MA ZIP: 02043 BUSINESS PHONE: 908-938-5561 MAIL ADDRESS: STREET 1: 25 RECREATION PARK DR SUITE 108 CITY: HINGHAM STATE: MA ZIP: 02043 FORMER COMPANY: FORMER CONFORMED NAME: STEMCELLS INC DATE OF NAME CHANGE: 20000524 FORMER COMPANY: FORMER CONFORMED NAME: CYTOTHERAPEUTICS INC/DE DATE OF NAME CHANGE: 19930328 8-K 1 form8-k.htm
0000883975 false 0000883975 2023-08-15 2023-08-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 15, 2023

 

MICROBOT MEDICAL INC.

(Exact name of registrant as specified in its charter)

 

Delaware   000-19871   94-3078125

(State or other jurisdiction

of incorporation)

   (Commission  
File Number)		  

(IRS Employer

Identification No.)

 

288 Grove Street, Suite 388

Braintree, MA 02184

(Address of Principal Executive Offices) (Zip Code)

 

Registrant’s telephone number, including area code: (781) 875-3605

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.01 par value   MBOT   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging Growth Company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

   
 

 

Item 7.01 Regulation FD Disclosure.

 

On August 15, 2023, Microbot Medical Inc., a Delaware corporation (the “Company”), issued a press release to announce the signing of a manufacturing agreement with B.Y. Medimor Ltd., a leading full turnkey manufacturer, to further strengthen the Company’s progression towards expected first in human clinical trials, as well as to manufacture the initial LIBERTY systems that are expected to be marketed following the completion of regulatory requirements.

 

The press release, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K, is incorporated herein by reference. The information in this Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information in this Item 7.01 or Exhibit 99.1.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
     
99.1   Press release dated August 15, 2023
     
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

   
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  MICROBOT MEDICAL INC.
   
  /s/ Harel Gadot
  Harel Gadot
  Chairman, President and Chief Executive Officer
   
Date: August 15, 2023  

 

   

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

Microbot Medical Boosts Manufacturing and Commercialization Capabilities for its Robotic Surgical System

 

The Agreement with a leading full turnkey manufacturer further strengthens the Company’s progression towards expected first in human clinical trials followed by regulatory approval and commercialization

 

BRAINTREE, Mass., August 15, 2023 – Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY® Robotic Surgical System, the first single-use endovascular robotic system, announces another step in its commitment to advance the commercialization processes of LIBERTY® with the signing of a manufacturing agreement with B.Y. Medimor Ltd.

 

The agreement governs the manufacturing of the Company’s LIBERTY® Robotic Surgical System, for its first in human clinical trial as well as for the initial LIBERTY systems that are expected to be marketed following the completion of regulatory requirements.

 

Medimor provides new product introduction (NPI) solutions and full turnkey manufacturing for medical devices as a one stop shop contract manufacturing service, including integration, parts cleaning, clean room assembly and testing.

 

“We continue our transition from a research and development stage to a clinical and commercial stage in the field of endovascular robotics,” commented Simon Sharon, Microbot’s CTO and General Manager. “We believe that the manufacturing agreement supports our efforts to deliver a state-of-the-art advanced robotic system and facilitates our next steps.”

 

About Microbot Medical

 

Microbot Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, with the goals of improving clinical outcomes for patients and increasing accessibility through the natural and artificial lumens within the human body.

 

The LIBERTY® Robotic Surgical System aims to improve the way surgical robotics are being used in endovascular procedures today, by eliminating the need for large, cumbersome, and expensive capital equipment, while reducing radiation exposure and physician strain. The Company believes the LIBERTY® Robotic Surgical System’s remote operation has the potential to be the first system to democratize endovascular interventional procedures.

Further information about Microbot Medical is available at http://www.microbotmedical.com.

 

 

 

 

 

Safe Harbor

 

Statements to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the development and/or commercialization of LIBERTY, the outcome of its studies to evaluate LIBERTY, whether the Company’s core business focus program and cost reduction plan are sufficient to enable the Company to continue to focus on its LIBERTY technology while it stabilizes its financial condition and seeks additional working capital, any failure or inability to recruit physicians and clinicians to serve as primary investigators to conduct regulatory studies which could adversely affect or delay such studies, uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, lingering uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required by law.

 

Investor Contact:

 

Michal Efraty

+972-(0)52-3044404

IR@microbotmedical.com

 

 

 

 GRAPHIC 3 ex99-1.jpg begin 644 ex99-1.jpg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end EX-101.SCH 4 mbot-20230815.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 mbot-20230815_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 mbot-20230815_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Aug. 15, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 15, 2023
Entity File Number 000-19871
Entity Registrant Name MICROBOT MEDICAL INC.
Entity Central Index Key 0000883975
Entity Tax Identification Number 94-3078125
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 288 Grove Street
Entity Address, Address Line Two Suite 388
Entity Address, City or Town Braintree
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02184
City Area Code (781)
Local Phone Number 875-3605
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 par value
Trading Symbol MBOT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0000883975 2023-08-15 2023-08-15 iso4217:USD shares iso4217:USD shares 0000883975 false 8-K 2023-08-15 MICROBOT MEDICAL INC. DE 000-19871 94-3078125 288 Grove Street Suite 388 Braintree MA 02184 (781) 875-3605 false false false false Common Stock, $0.01 par value MBOT NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://microbotmedical.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm mbot-20230815.xsd mbot-20230815_lab.xml mbot-20230815_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "mbot-20230815_lab.xml" ] }, "presentationLink": { "local": [ "mbot-20230815_pre.xml" ] }, "schema": { "local": [ "mbot-20230815.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "MBOT", "nsuri": "http://microbotmedical.com/20230815", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "AsOf2023-08-15", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://microbotmedical.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "AsOf2023-08-15", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://microbotmedical.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001493152-23-028838-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-028838-xbrl.zip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